The role of genotype in 104 cases of diffuse large B-Cell lymphoma primary of breast

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 2, 2012, Pages 126-129

  Aviles, Agustin ^a,b   Neri, Natividad ^a   Nambo, M Jesus ^a  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b NONE   (Mexico)

Author keywords

Anthracycline; Breast lymphoma; Extranodal lymphoma; Genotype profile; Rituximab

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA PRIMARY OF BREAST; DISEASE FREE SURVIVAL; FEMALE; GENETIC ANALYSIS; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ANALYSIS OF VARIANCE; BREAST TUMOR; FOLLOW UP; GENETICS; IMMUNOLOGY; MIDDLE AGED; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84860696115     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318209aa12     Document Type: Article

References (27)

1. DeJong D, Rosenwald A, Chlanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite broad clinical applications. J Clin Oncol. 2007;25:805-812. (Pubitemid 350002880)
2. Gleissner B, Küppers R, Siebert R, et al. Report of a workshop on malignant lymphoma; a review profiling. Br J Haematol. 2008;142:166-178. (Pubitemid 351994054)
3. Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast: Prognostic factors and outcome of a study by the International Extranodal Lymphoma Study Group. Ann Oncol. 2008;19:233-241. (Pubitemid 351201702)
4. Ganjoo K, Advani R, Mariappan MR, et al. Non-Hodgkin's lymphoma of the breast. Cancer. 2007;110:25-30.
5. Jeanneret-Sozzi W, Taghian A, Epelbaum R, et al. Primary breast lymphoma: Patient profile, outcome and prognostic factors. BMC Cancer. 2008;8:8.
6. Talwalkar SS, Miranda RN, Valbuena JR, et al. Lymphomas involving the breast. Am J Surg Pathol. 2008;32:1299-1309.
7. Lin YC, Tsai CH, Wu JS, et al. Clinicopathological features and treatment outcome of non-Hodgkin's lymphoma of the breast. Leuk Lymphoma. 2009;50:918-924.
8. Lossos IS, Czerwinski JK, Alizadeth AA, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350:1828-1833.
9. Zinzani PL, Dirnhofer S, Sabatini E, et al. Identification of outcome predictors in diffuse large B-cell lymphoma: Immunohistochemical profiling of homogenous treated de novo tumor with nodal presentation on tissue microarray. Haematologica. 2005;90:341-347. (Pubitemid 40388984)
10. Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation Bcell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol. 2004;28:464-470. (Pubitemid 38436519)
11. Yoshida S, Nakamura S, Saki Y, et al. Primary breast lymphoma shows a non-germinal B-center phenotype. Mod Pathol. 2005; 18:398-405. (Pubitemid 40395359)
12. Nyman H, Adde M, Karjalainen ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma treated with immunotherapy. Blood. 2007;109:4930-4935. (Pubitemid 46827791)
13. Fu K, Weisenburguer DD,WilliamWL, et al. Addition of Rituximab to standard chemotherapy improves the survival of both the germinal center B-cell like and non-germinal B-cell like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008;26:587-594.
14. Molina T, Gaulard P, Jais JP. Germinal center phenoptype determined by immunohistochemistry does no correlate with outcome in diffuse large -B cell lymphoma treated with immunochemotherapy in the randomized trial LNH1798. Blood. 2007; 110(Suppl 1):63 (Abstract 51).
15. Gutierrez-García E, Colomo L, Villamor N. Non benefit from Rituximab containing regimens in primary extranodal diffuse large B-cell lymphoma. Blood. 2008;112(Suppl 1):886 (Abstract 3615).
16. Hans CP, Weisenburguer DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-282. (Pubitemid 38029949)
17. Avilés A, Delgado S, Nambo MJ, et al. Primary breast lymphoma: Results of a controlled clinical trial. Oncology. 2005;69:256-260. (Pubitemid 41433584)
18. Avilés A, Castañeda C, Neri N, et al. Rituximab and dose dense chemotherapy in primary breast lymphoma. Haematologica. 2007; 92:1147-1148. (Pubitemid 350153469)
19. The International non-Hodgkin's lymphoma prognostic factors project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
20. Ilíc I, Mitrovíc Z, Aurere I, et al. Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell patients treated with CHOP-like chemotherapy with and without rituximab. Int J Haematol. 2009;90:74-80.
21. Lin CH, Kuo KT, Chang SS, et al. Comparison of the expression of prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res. 2006;12:1152-1156.
22. Al-Abbadi MA, Hattab EM, Tarweneh M, et al. Primary testicular diffuse large B-cell lymphoma belongs to the non-germinal center B-cell like subgroup. Mod Pathol. 2006;19:1521-1527. (Pubitemid 44789919)
23. Sato Y, Nauko O, Morito T, et al. Patients with primary nontonsilar oral diffuse large B-cell lymphoma exhibit favorable prognosis despite non-germinal center B-cell like phenotype. Cancer Sci. 2009;100:43-46.
24. Mitchel KA, Finn WG, Owens SR. Differences in germinal centre and non-germinal centre phenotype in gastric and intestinal diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49:1717-1723.
25. Sarosiek K, Nechustan H, Lu X, et al. Interleukin-4 distinctively modifies responses of germinal centre-like and activated-B-cell like diffuse large B-cell lymphomas to immunotherapy. Br J Haematol. 2009;147:308-318.
26. Held G, Pfreundschuh M. Germinal center or non-germinal center BLBCL. Nat Rev Clin Oncol. 2009;6:188-189.
27. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC rearragements are associated with a poor prognosis in diffuse large-B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114:3533-3537.